Evidence map›Paper›PMID 28480768›Full record

ReviewExpert opinion on pharmacotherapy2017

Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.

Timothy N Clinton, Solomon L Woldu, Ganesh V Raj

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on pharmacotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Timothy N Clintona Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA.
Solomon L Woldua Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA.
Ganesh V Raja Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA.
The University of Texas Southwestern Medical Center · US

Funding

Physician Scientist Oncology Training ProgramT32CA136515 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SKAPEK, STEPHEN X · 2009 to 2018
$2.2M
NCI NIH HHS T32 CA136515
6 · The paper itself

Abstract

introductionAndrogen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits and disadvantages over traditional LHRH agonist therapy. Expert opinion: Degarelix represents a newer class of ADT that results in a rapid and reliable decline in serum testosterone, a quality that makes it particularly advantageous in men presenting with symptomatic, hormone-sensitive prostate cancer. Due to differences in mechanism of action, there is observational data suggesting a potential cardiovascular and even oncologic benefit over traditional LHRH agonist therapy. Further research is ongoing to more clearly define this potential benefit.

Indexed as

Androgen AntagonistsAntineoplastic Agents, HormonalDrug-Related Side Effects and Adverse ReactionsGonadotropin-Releasing HormoneHumansMaleOligopeptidesOrchiectomyProstatic NeoplasmsRandomized Controlled Trials as TopicTreatment Outcomeacetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamideAndrogen AntagonistsAntineoplastic Agents, HormonalGonadotropin-Releasing HormoneOligopeptidesandrogen deprivation therapyDegarelixGnRH antagonistLHRH agonistprostate cancer

Identifiers

PMID28480768
PMCPMC7171911
OpenAlexW2612378460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.